ArticleFrontiers in pharmacology2026
Albumin administration and 28-day mortality in sepsis-induced myocardial injury: a propensity score-matched analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current evidence on the therapeutic effects of albumin administration in critically ill patients with sepsis-induced myocardial injury (SIMI) remains insufficient. To address this knowledge gap, we performed a retrospective cohort study to examine the association between albumin supplementation and key clinical outcomes in this patient population. Methods: This study included adult patients with SIMI who were treated in the intensive care unit (ICU). Data were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database (version 2.2). Patients were categorized into two groups based on whether they received albumin infusion during their ICU stay: the albumin group and the non-albumin group. The primary endpoint was all-cause 28-day mortality. Kaplan-Meier (KM) curves were constructed to estimate survival probabilities, and log-rank tests were used to compare survival distributions between the two groups. Subgroup analyses were performed to explore heterogeneity in treatment effects and to assess the association of albumin infusion with outcomes across different patient characteristics. Results: A total of 433 patients were included in the albumin infusion group and 1126 in the non-albumin infusion group. After 1:1 propensity score matching (PSM), 648 patients were included in the analysis (324 in each group). Following PSM, no statistically significant differences were observed in mortality outcomes between the albumin and non-albumin groups: 28-day mortality (HR = 0.97, 95% confidence interval[CI]: 0.57-1.64, p = 0.90), 60-day mortality (HR = 0.89, 95%CI 0.56-1.41, p = 0.63), 90-day mortality (HR = 0.89, 95%CI 0.57-1.39, p = 0.61), and in-hospital mortality (HR = 0.85, 95%CI 0.55-1.33, p = 0.49). Notably, the albumin group exhibited significantly prolonged ICU length of stay (9.06 [4.65, 16.72] vs. 5.65[2.76, 10.50] days, P<0.01) and hospital length of stay (22.56 [13.42, 34.05] vs. 14.50 [8.32, 22.36] days, P<0.01) compared to the non-albumin group. Conclusion: In this propensity score-matched cohort of critically ill patients with sepsis-induced myocardial injury, albumin-based resuscitation strategy demonstrated comparable 28-day survival outcomes to crystalloid-focused fluid management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.